Welcome to our dedicated page for McKesson news (Ticker: MCK), a resource for investors and traders seeking the latest updates and insights on McKesson stock.
McKesson Corporation (NYSE: MCK) is a diversified healthcare services and pharmaceutical distribution company that regularly issues news and updates relevant to investors, healthcare partners, and other stakeholders. The company describes itself as dedicated to advancing health outcomes for patients everywhere, partnering with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services that support access to quality care.
The McKesson news feed typically features announcements about quarterly and annual financial results, earnings release dates, and related investor webcasts. These updates often include information about fiscal guidance, long-term financial targets, and commentary on strategic priorities and business outlook shared during events such as Investor Day.
In addition to earnings and guidance, McKesson’s news includes Board actions such as dividend declarations, reflecting decisions on returning capital to shareholders. The company also issues releases on organizational and segment reporting changes, including the introduction of its North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions segments, along with portfolio developments like planned separations or divestitures.
McKesson may also appear in third-party announcements highlighting distribution agreements and collaborations that illustrate its role in pharmaceutical distribution and healthcare services. Such items can show how McKesson supports access to therapies through its distribution networks and healthcare supply chain capabilities.
For readers tracking MCK news, this page provides a centralized view of financial announcements, strategic updates, capital allocation decisions, and partnership-related developments. Regularly reviewing these items can help investors and observers understand how McKesson communicates its performance, segment evolution, and strategic focus within the healthcare and wholesale trade landscape.
McKesson Corporation (NYSE: MCK) has announced it will release its first quarter fiscal 2026 financial results after market close on Wednesday, August 6, 2025. The company will host a live webcast earnings conference call for investors at 4:30 PM Eastern Time to discuss the financial results. Both the live and archived versions of the audio webcast will be accessible through McKesson's Investor Relations website.
Summary not available.
McKesson (NYSE: MCK) has completed its acquisition of a controlling interest in PRISM Vision Holdings, a leading provider of ophthalmology and retina management services. The transaction values at approximately $850 million for an 80% stake, while PRISM physicians retain the remaining 20% interest.
The strategic acquisition aims to establish McKesson as a leading platform in retinal and ophthalmology services, enhancing its differentiated value proposition, clinical services, and distribution offerings. The company also announced it will release its fourth quarter and full year fiscal 2025 financial results after market close on May 8, 2025, followed by an earnings conference call at 4:30 PM Eastern Time.
McKesson (NYSE: MCK) has announced its financial results for the third quarter of fiscal year 2025. The company has also raised its full-year adjusted EPS guidance. The detailed financial results are available on McKesson's Investor Relations website. The company is hosting a live webcast earnings conference call on February 5th at 4:30 PM ET to discuss the results with investors. The webcast, earnings release, financial tables, and presentation slides will be accessible on McKesson's Investor Relations platform.
McKesson (NYSE: MCK) has announced a definitive agreement to acquire an 80% controlling interest in PRISM Vision Holdings for approximately $850 million. PRISM Vision physicians will retain the remaining 20% interest. PRISM Vision is a premier provider of general ophthalmology and retina management services, operating with more than 180 providers across 91 office locations and seven ambulatory surgery centers.
The acquisition will be consolidated within McKesson's U.S. Pharmaceutical segment and is expected to be $0.20 to $0.30 accretive to McKesson's Adjusted Earnings Per Diluted Share in the first 12 months, growing to $0.65 to $0.75 by the end of the third year. The transaction aims to strengthen McKesson's position in retina and ophthalmology care, expand data and analytics capabilities, and enhance clinical research opportunities.
McKesson (NYSE:MCK) has announced its Board of Directors has declared a quarterly dividend of $0.71 per share of common stock. The dividend will be distributed to shareholders of record as of March 3, 2025, with the payment scheduled for April 1, 2025.
McKesson (NYSE: MCK) has successfully completed the divestiture of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm, on December 30, 2024. The transaction, which was initially announced in September 2024, aligns with McKesson's strategic focus on capital deployment and prioritization of investments in expanding its oncology and biopharma growth platforms.
FAQ
What is the current stock price of McKesson (MCK)?
What is the market cap of McKesson (MCK)?
